EUCTR2015-003529-33-HU进行中（未招募）1 期
A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved diabetic macular edema (DME)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients 18 years of age and older
- •- Male patients or female patients of non-childbearing potential
- •- Diagnosis of Diabetes mellitus type 1 or type 2 with stable antidiabetic medication (stable medication defined as: no change in oral antidiabetic medication and/or no initiation of intensive insulin treatment within 3 months prior to randomization or plans to do so in the next 4 months)
- •- Retinal thickening due to Diabetic macular edema (DME) involving the center of the macula in the study eye as confirmed by the Investigator on clinical exam
- •- Center-involved DME confirmed on Spectral-Domain Optical Coherence Tomography (SD-OCT) with central subfield thickness (CSFT) of at least 300 µm in the study eye at screening, confirmed by Central Reading Centre
- •- Best corrected visual acuity ETDRS letter score in the study eye of 84 or below but at least 70, at screening
- •- Further inclusion criteria apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 59
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 41
排除标准
- •- Macular edema considered to be due to other causes than DME in the study eye
- •- Additional eye disease in the study eye that, in the opinion of the Investigator, might affect macular edema or could compromise or alter visual acuity during the course of the trial
- •- Anterior segment and vitreous abnormalities in the study eye that would compromise the adequate assessment of the best corrected visual acuity or an adequate examination of the posterior pole
- •- Intraocular surgery in the study eye within 4 months prior to randomization or planned intraocular surgery, including cataract, during the study period
- •- Proliferative diabetic retinopathy or iris neovascularisation in the study eye
- •- Aphakia in the study eye
- •- Any indication that requires immediate treatment or for which treatment is expected in the study eye with anti-VEGF or with laser photocoagulation during the period, as per Investigator's judgment
- •- History of prior laser photocoagulation or other surgical, intravitreal or peribulbar treatment in the study eye within 4 months prior to randomization, either for DME or an ocular condition other than DME
- •- History of fluocinolone acetonide intravitreal implant in the study eye
- •- Application of intraocular corticosteroids in the study eye within 2 years prior to randomization in phakic eyes or 9 months in pseudophakic eyes
- •- History of topical steroid or nonsteroidal anti-inflammatory drugs (NSAID) treatment in the study eye within 30 days prior to randomization
- •- Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization
- •- Initiation of intensive insulin treatment (multiple daily injections or a pump) within 3 months prior to randomization or plans to do so in the next 4 months
- •- Change in oral antidiabetic medication within 3 months prior to randomization
- •- Patients with a clinically relevant abnormal screening haematology, blood chemistry, or urinalysis
- •- Renal impairment with estimated creatinine clearance < 30 mL/min (as calculated by Cockcroft-Gault equation)
- •- Myocardial infarction or unstable angina pectoris within 3 months before randomization
- •- Uncontrolled arterial hypertension defined as a single measurement of systolic >180 mmHg, two consecutive measurements of systolic >160 mmHg, or diastolic >100mmHg on optimal medical regimen
- •- Further exclusion criteria apply
研究者
相似试验
进行中（未招募）
1 期
Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edemaPatients with mild visual impairment due to center-involved diabetic macular edema (DME)MedDRA version: 18.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2015-003529-33-BESCS Boehringer Ingelheim Comm.V125
进行中（未招募）
1 期
A study that tests BI 1467335 in patients with diabetic eyedisease (diabetic retinopathy). It looks at the way BI 1467335 istaken up, the effects it has, and how well it is tolerated.diabetic retinopathyEUCTR2016-002971-91-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.100
进行中（未招募）
1 期
A study that tests BI 1467335 in patients with diabetic eyedisease (diabetic retinopathy). It looks at the way BI 1467335 istaken up, the effects it has, and how well it is tolerated.diabetic retinopathyEUCTR2016-002971-91-GRBoehringer Ingelheim Ellas SA100
进行中（未招募）
1 期
Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edemaEUCTR2015-003529-33-ESBoehringer Ingelheim España, S.A.125
进行中（未招募）
1 期
Safety and effect on central retinal thickness of BI 1026706 in patients with diabetic macular edemaPatients with mild visual impairment due to center-involved diabetic macular edema (DME)MedDRA version: 19.1 Level: LLT Classification code 10057934 Term: Diabetic macular edema System Organ Class: 100000004853EUCTR2015-003529-33-PTnilfarma - União Internacional de Lab. Farmacêuticos, Lda169